Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer: A Phase 2 Randomized, Open-Label Study

NCT05826964 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

NCT NCT05826964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05826964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer: A Phase 2 Randomized, Open-Label Study
Lead sponsor
University of Miami
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 12, 2023
Completion date
July 31, 2029
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, er-positive breast cancer, her2-negative breast cancer, metastatic breast cancer